- Home
- COCP vs NERV Comparison
COCP vs NERV Comparison
Compare COCP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- NERV
- Stock Information
- Founded
- COCP N/A
- NERV 2007
- Country
- COCP United States
- NERV United States
- Employees
- COCP N/A
- NERV N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- NERV Health Care
- Exchange
- COCP Nasdaq
- NERV Nasdaq
- Market Cap
- COCP 18.3M
- NERV 18.3M
- IPO Year
- COCP N/A
- NERV 2014
- Fundamental
- Price
- COCP $2.15
- NERV $2.20
- Analyst Decision
- COCP Strong Buy
- NERV Hold
- Analyst Count
- COCP 1
- NERV 1
- Target Price
- COCP $7.00
- NERV $5.00
- AVG Volume (30 Days)
- COCP 22.2K
- NERV 25.3K
- Earning Date
- COCP 11-13-2024
- NERV 11-05-2024
- Dividend Yield
- COCP N/A
- NERV N/A
- EPS Growth
- COCP N/A
- NERV N/A
- EPS
- COCP N/A
- NERV N/A
- Revenue
- COCP N/A
- NERV N/A
- Revenue This Year
- COCP N/A
- NERV N/A
- Revenue Next Year
- COCP N/A
- NERV N/A
- P/E Ratio
- COCP N/A
- NERV N/A
- Revenue Growth
- COCP N/A
- NERV N/A
- 52 Week Low
- COCP $1.33
- NERV $2.10
- 52 Week High
- COCP $3.10
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- COCP 64.04
- NERV 34.31
- Support Level
- COCP $1.65
- NERV $2.26
- Resistance Level
- COCP $1.82
- NERV $2.43
- Average True Range (ATR)
- COCP 0.17
- NERV 0.16
- MACD
- COCP 0.03
- NERV -0.01
- Stochastic Oscillator
- COCP 64.10
- NERV 13.71
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.